| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:1804.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Graduate Institute of Epidemiology, College of Public Health, National Taiwan University (C.-H.W., C.-L.C., L.-I.H., C.-J.C.); the Department of Cardiology, Taipei Municipal Chung-Hsiao Hospital (C.-H.W.); the Department of Neurology, College of Medicine, National Taiwan University (P.-K.Y., J.-S.J.); School of Public Health, Taipei Medical University (Y.-M.H., H.-Y.C.); and Institute of Biomedical Sciences, Academia Sinica (M.-M.W.), Taiwan.
Correspondence to Dr Chien-Jen Chen, College of Public Health, National Taiwan University, 1 Jen-Ai Road Section 1, Taipei 100, Taiwan. E-mail cjchen{at}ha.mc.ntu.edu.tw
| Abstract |
|---|
|
|
|---|
Methods and Results We studied 199 male and 264 female adult residents from the southwestern area of endemic arseniasis in Taiwan. The extent of carotid atherosclerosis was assessed by duplex ultrasonography. Diabetes mellitus was determined by oral glucose tolerance test, hypertension by mercury sphygmomanometers, and serum lipid profiles by autoanalyzers. Information regarding the consumption of high-arsenic artesian well water, cigarette smoking, and alcohol consumption was obtained through standardized questionnaire interviews. Logistic regression analysis was used to estimate the odds ratio and its 95% CI of carotid atherosclerosis for various risk factors. Three indices of long-term exposure to ingested arsenic, including the duration of consuming artesian well water, the average arsenic concentration in consumed artesian well water, and cumulative arsenic exposure, were all significantly associated with prevalence of carotid atherosclerosis in a dose-response relationship. The biological gradient remained significant after adjustment for age, sex, hypertension, diabetes mellitus, cigarette smoking, alcohol consumption, waist-to-hip ratio, and serum levels of total cholesterol and LDL cholesterol. The multivariate-adjusted odds ratio was 3.1 (95% CI 1.3 to 7.4) for those who had a cumulative arsenic exposure of
20 mg/L-years compared with those without exposure to arsenic from drinking artesian well water.
Conclusions Carotid atherosclerosis is associated with ingested inorganic arsenic, showing a significant biological gradient.
Key Words: arsenic atherosclerosis dose-response relationship
| Introduction |
|---|
|
|
|---|
Ingested arsenic has long been associated with the development of blackfoot disease (BFD), a unique peripheral vascular disease that was endemic in the southwestern coastal area of Taiwan.3,4 Clinically, the disease begins with coldness and/or numbness of the lower extremities, progresses over several years to intermittent claudication, and ends with dry gangrene and spontaneous amputation of the affected extremities.3 The pathological change of BFD is compatible with arteriosclerosis obliterans (70%) and thromboangiitis obliterans (30%), and the fundamental vascular change of BFD is an unduly developed severe atherosclerosis.5 Long-term exposure to arsenic has been found to be associated with an increased risk of diabetes mellitus, hypertension, ischemic heart disease, and cerebral infarction in a dose-response relationship.69
Ultrasonographic evaluation of the superficial carotid artery is a noninvasive and cost-effective tool for the assessment of carotid atherosclerosis. Subclinical lesions such as stenosis and plaque formation are relatively late manifestations of the atherosclerosis process.10,11 Progression of intimal-medial thickness (IMT) may reflect earlier changes.11 The specific aim of this study was to assess the dose-response relationship of carotid atherosclerosis with long-term exposure to ingested inorganic arsenic through the consumption of artesian well water. High-resolution color duplex ultrasonography was used in this study to evaluate the extent and severity of the extracranial carotid artery (ECCA) as an indicator of atherosclerosis.
| Methods |
|---|
|
|
|---|
Study Subjects
The recruitment of study subjects was described in detail previously.7 In brief, all adult residents who lived >6 months in the study area were selected from records of the local household registration bureau, where demographic status and events including birth, marriage, education, migration, employment, and death of all family members in every household are mandatorily registered and updated annually. Household visits were carried out to interview residents who lived in the study area
5 days a week and to invite them to participate in health examination. Six follow-up health examinations have been carried out since the initial recruitment. The ultrasonographic assessment of ECCA atherosclerosis was conducted in the sixth examination in 1996. During this examination, a total of 463 cohort members were invited, and 436 (94%) of them completed the ultrasonographic assessment of ECCA.
Questionnaire Interview and Arsenic Exposure
A standardized personal interview of study subjects based on a structured questionnaire was carried out by well-trained public health nurses. Information obtained from the interview included socioeconomic and demographic characteristics, alcohol intake, cigarette smoking, physical activities, dietary consumption frequency, residential and water consumption history, and personal and family history of hypertension, diabetes, and cardiovascular diseases. Information regarding cigarette smoking habits was obtained, including age at starting cigarette smoking, average number of cigarettes smoked per day, and age at stopping smoking. Age at starting regular consumption of alcoholic beverages, average frequency of alcohol intake per week, average quantity of alcohol consumption, and age at stopping alcohol drinking were also obtained.
A detailed residential history, including villages of residence and duration of residence, and a history of water consumption, including water source and duration of consumption, were obtained on the basis of the questionnaire interview. The levels of arsenic in artesian well water of the villages where the study subjects had lived were obtained from reports of previous studies carried out in the 1960s.12
Some study subjects had moved from one village to another, and the arsenic concentrations in the artesian well water of these villages were different. An index of cumulative arsenic exposure was derived to reflect the overall exposure to arsenic for each study subject. The cumulative arsenic exposure (in mg/L-years) was defined as the sum of products derived by multiplying the arsenic concentration in well water (mg/L-years) by the duration of consuming the artesian well water (years) during consecutive periods of living at different villages. In other words, the cumulative arsenic exposure equaled
(CixDi), where Ci was the median arsenic concentration in artesian well water of a village in which a given subject lived during the period i, and Di was the duration of drinking artesian well water in the village during the period i. An index of average arsenic concentration in artesian well water was also derived by the formula
(CixDi)/
(Di).
Assessment of Carotid Atherosclerosis
An ultrasonographic assessment of ECCA atherosclerosis was performed with a Hewlett-Packard Sono 1000 equipped with a 7.5-MHz frequency in B-mode and 5.6-MHz frequency in pulsed Doppler mode. The duplex scanning was performed by neurologists and a cardiologist while study subjects were lying in the supine position with the head slightly extended and rotated 45° away from the side being examined. Transverse and longitudinal scans were performed to assess the common carotid artery, carotid bifurcation, and internal and external carotid arteries.
Plaque of the carotid artery was defined as irregular surface, lumen encroachment, significant wall thickening
50% of adjacent IMT, and/or structure heterogeneity such as acoustic shadow. The IMT was measured in the far wall of 3 segments of bilateral ECCAs. Three segments were identified on each side: the distal 1.0 cm of the common carotid artery proximal to the bifurcation, the bifurcation itself, and the proximal 1.0 cm of the internal carotid artery. The IMT was estimated as the mean of these 6 measurements. Three carotid atherosclerosis indices (CAIs) were defined as follows: CAI-1, presence of plaque or IMT
1.0 mm; CAI-2, IMT
1.0 mm; and CAI-3, presence of plaque.
Laboratory Examinations
Fasting blood samples were collected from study subjects for testing of serum levels of total cholesterol, HDL cholesterol, triglycerides, and uric acid by standardized autoanalyzers. Glucose tolerance tests were also performed. The status of diabetes mellitus was defined as (1) a fasting glucose level of
7.8 mmol/L, (2) a 2-hour glucose level
11.1 mmol/L, or (3) a history of diabetes mellitus regularly treated with oral hypoglycemic agents or insulin. Anthropometric characteristics, including height, weight, waist circumference, hip circumference, systolic blood pressure, and diastolic blood pressure, were measured according to a standard protocol. Blood pressures were measured 3 times with a mercury sphygmomanometer with study subjects sitting. The average of 3 measurements was used for analysis. Hypertension was defined as (1) an average systolic blood pressure
160 mm Hg, (2) an average diastolic blood pressure
95 mm Hg, or (3) a history of hypertension regularly treated with antihypertensive agents.
Statistical Analysis
The age-and-sexspecific prevalences of carotid atherosclerosis were estimated for CAI-1, CAI-2, and CAI-3, respectively. A
2 test for trend was used to examine the statistical significance of the biological gradient of CAIs with age. The differences in CAIs between men and women were tested by Mantel-Haenszel
2 tests with adjustment for age. The dose-response relationships between CAIs and long-term arsenic exposure were assessed after adjustment for age and sex. The biological gradients were assessed by the duration of consuming artesian well water, average arsenic concentration in artesian well water, and cumulative arsenic exposure, respectively. Multiple logistic regression analysis was used to examine the associations between CAIs and arsenic exposure with further adjustment for various cardiovascular risk factors. All continuous variables of cardiovascular risk factors were categorized into 2 to 4 groups. The regression coefficients and their standard errors were used to derive odds ratios (ORs) and their 95% CIs for various variables.
| Results |
|---|
|
|
|---|
|
Cardiovascular Risk Factors and Carotid Atherosclerosis
Table 1 shows the prevalence of CAIs by various cardiovascular risk factors. A dose-response relationship was observed between CAIs and serum level of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. All the biological gradients were statistically significant after adjustment for age and sex (all probability values <0.05). Those who had higher body mass index or waist-to-hip ratio had a higher prevalence of CAIs. The associations were more striking for waist-to-hip ratio than for body mass index. Study subjects affected with diabetes mellitus or hypertension had increased prevalences of CAIs.
|
Long-Term Arsenic Exposure and Carotid Atherosclerosis
Figure 2 shows the prevalences of CAIs by long-term exposure to ingested arsenic. There were significant dose-response relationships between CAI prevalence and 3 arsenic exposure indices. The longer the duration of consuming artesian well water, the higher the prevalence of CAIs. The higher the average concentration of arsenic in consumed artesian well water, the higher the prevalence of CAIs. The higher the cumulative arsenic exposure, the higher the prevalence of CAIs. As shown in Table 2, the biological gradients remained statistically significant after adjustment for age, sex, serum levels of total and LDL cholesterol, waist-to-hip ratio, diabetes mellitus, and hypertension. The probability values for trend were 0.008, 0.015, and 0.045 for CAI-1, CAI-2, and CAI-3, respectively. Subjects with the highest cumulative arsenic exposure (
20 mg/L-years) had an increased risk of developing carotid atherosclerosis over those with the lowest arsenic exposure after adjustment for all other risk factors. The multivariate-adjusted ORs were 3.1 (95% CI 1.3 to 7.4), 2.9 (95% CI 1.2 to 6.9), and 2.3 (95% CI 0.8 to 6.4) for CAI-1, CAI-2, and CAI-3, respectively.
|
|
| Discussion |
|---|
|
|
|---|
Morbidity and mortality from ischemic heart disease and cerebral infarction may be considered late clinical manifestations of long-term arsenic exposure. These late health end points result from the interaction of both predisposing and precipitating factors for cardiovascular diseases. The risk assessment based on these late cardiovascular events might be underestimated because of the competing causes of death and the accuracy in the diagnosis of sudden death from ischemic heart disease or stroke. Carotid atherosclerosis indexed by IMT and/or plaque is a subclinical lesion and can be detected by ultrasonography before clinical events develop. The association between arsenic exposure and carotid atherosclerosis, however, has never been reported previously. In this article, we have demonstrated for the first time that long-term arsenic exposure is significantly associated with an increased risk of carotid atherosclerosis, showing a dose-response relationship after adjustment for other cardiovascular risk factors, including age, sex, hypertension, diabetes mellitus, dyslipidemia, cigarette smoking, and alcohol consumption. On the basis of this prominent biological gradient, this finding strongly indicates that long-term arsenic exposure may lead to the progression and/or acceleration of carotid atherosclerosis and most likely generalized atherosclerosis.
The pathology of BFD had been extensively studied in 63 amputated parts of extremities from 51 BFD patients from southwest Taiwan. The pathology of BFD was compatible with 2 distinct types: arteriosclerosis obliterans and thromboangiitis obliterans.5 In 3 autopsy cases of BFD, the common pathological finding is generalized atherosclerosis involving large, medium-size, and small arteries.5 Interestingly, in an autopsy case of a 24-year-old woman with thromboangiitis obliteranstype BFD, severe atherosclerosis of coronary and other medium-size arteries was found.5 An autopsy finding on children in Antofagasta, Chile, with chronic arsenic intoxication had shown systemic arterial intimal thickening in small and medium-size arteries involving the heart, gastrointestinal tract, liver, skin, and pancreas.16 Therefore, accelerated arteriosclerosis can occur under chronic arsenic induction in the absence of traditional coronary risk factors. Moreover, researchers also found abnormal peripheral microcirculation in clinically normal subjects with a past history of chronic arsenic exposure.17
In many species, inorganic arsenic is methylated to monomethylated, dimethylated, and trimethylated metabolites.18,19 S-adenosylmethionine is the major source of methyl group donors.20 Because of the involvement of S-adenosylmethionine, the homocysteine level may be increased through the methylation pathway of inorganic arsenic. Hyperhomocysteinemia has been known to be associated with increased risk of cardiovascular disease.2123
The inhibitory effects of arsenic on individual cells are in the mitochondrial respiratory function and are highly preferential in the NAD-linked substrates, such as pyruvate dehydrogenase.24,25 The changes in mitochondrial protein synthesis and inner-membrane structural integrity might also play an important role for arsenic toxicity.24,25 Disruption of oxidative phosphorylation and a decrease in cellular production of ATP might result in formation of reactive oxygen species and induction of stress proteins.26,27 Disruption of mitochondrial respiratory function, oxidative stress, and alterations in the mitochondrial structure might result in cellular injury, necrosis, and/or apoptosis.2427
Moreover, epidemiological studies have demonstrated that arsenic, ionizing radiation, and vinyl chloride monomer may induce various cancers and vascular diseases, including angiosarcoma and atherosclerotic plaques.28 These findings suggest that somatic mutation and cell proliferation may play important roles in the dual effects on carcinogenesis and atherosclerosis. In support of arsenic-induced cell proliferation, researchers have demonstrated that sodium arsenite may induce increased mRNA transcripts of growth factors, including granulocyte-macrophage colonystimulating factor, transforming growth factor-
, and the inflammatory cytokine tumor necrosis factor-
.29 Therefore, inorganic arsenic may cause atherosclerosis through its roles in the induction of chromosomal abnormalities, oxidative stress, gene amplification, and alterations of growth factors and DNA repair.19 In addition, mercury accumulation in the human body was reported to be associated with accelerated progression of carotid atherosclerosis.30
From the strong dose-response relationship and biological plausibility for the association between arsenic exposure and carotid atherosclerosis, we conclude that long-term arsenic exposure is an independent risk factor for atherosclerosis and that carotid atherosclerosis is a novel biomarker for arseniasis. The impact of arsenic exposure on atherosclerosis and carcinogenesis needs to be considered simultaneously in the health risk assessment of arsenic. Regulatory levels such as the US Environmental Protection Agencys maximum contaminant level (MCL) for arsenic in drinking water have been lowered from 50 to 10 µg/L. In addition to the cancer risk, atherosclerosis has also been considered in the setting of the MCL by the Environmental Protection Agency on a qualitative basis. To determine the adequacy of the new MCL for protecting public health, the atherosclerotic effect needs to be quantified for the comprehensive health risk assessment of ingested inorganic arsenic at levels between 5 and 50 µg/L. Because of the small number of subjects at these levels in this study, we could not examine the dose-response relationship between ingested arsenic and carotid atherosclerosis by further categorizing the lowest exposure group of <50 µg/L into subgroups. Our present study in northeastern Taiwan, however, is collecting data on the prevalence of carotid atherosclerosis at lower arsenic concentrations, in particular 5 to 50 µg/L. In this study, we have established for the first time the biological gradient between ingested arsenic and carotid atherosclerosis before the development of clinical events such as acute myocardial infarction and stroke.
| Acknowledgments |
|---|
Received November 16, 2001; revision received February 5, 2002; accepted February 5, 2002.
| References |
|---|
|
|
|---|
2. Chen CJ, Hsu LI, Tseng CH, et al. Emergent epidemics of arseniasis in Asia.In: Chappell WR, Abernathy CO, Calderon RL, eds. Arsenic Exposure and Health Effects. Amsterdam, Netherlands: Elsevier; 1999: 113121.
3. Tseng WP. Effects and dose-response relationships of skin cancer and black foot disease with arsenic. Environ Health Prospect. 1977; 19: 109119.
4. Chen CJ, Wu MM, Lee SS, et al. Atherogenicity and carcinogenicity of high-arsenic artesian well water: multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis. 1988; 8: 452460.
5. Yeh S, How SW. A pathological study on the blackfoot disease in Taiwan. Rep Inst Pathol Natl Taiwan Univ. 1963; 14: 2573.
6. Tseng CH, Tai TY, Chong CK, et al. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect. 2000; 108: 847851.
7. Chen CJ, Hsueh YM, Lai MS, et al. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension. 1995; 25: 5360.
8. Chen CJ, Chiou HY, Chiang MH, et al. Dose-response relation between ischemic heart disease and mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol. 1996; 16: 504510.
9. Chiou HY, Huang WI, Su CL, et al. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke. 1997; 28: 17171723.
10. Salonen R, Salonen JT. Carotid atherosclerosis in relation to systolic and diastolic blood pressure: Kuopio Ischemic Heart Disease Risk Factor Study. Ann Med. 1991; 23: 2327.
11. Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-medial thickness distribution in general population as evaluated by B-mode ultrasound. Stroke. 1993; 24: 12971304.
12. Kuo TL. Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Rep Inst Pathol Natl Taiwan Univ. 1964; 20: 713.
13. Axelson O, Dahlgren E, Janssen CD, et al. Arsenic exposure and mortality: a case conference study from a Swedish copper smelter. Br J Ind Med. 1978; 35: 815.
14. Welch K, Higgins I, Oh M, et al. Arsenic exposure, smoking, and respiratory cancer in copper smelter workers. Arch Environ Health. 1982; 37: 325335.
15. Hansen ES. Mortality from cancer and ischemic heart disease in Danish chimney sweeps: a five-year follow-up. Am J Epidemiol. 1983; 117: 160164.
16. Rosenberg HG. Systemic arterial disease and chronic arsenicism in infants. Arch Pathol. 1974; 97: 360365.
17. Tseng CH, Chong CJ, Chen BJ, et al. Abnormal peripheral microcirculation in seemingly normal subjects living in blackfoot-disease-hyperendemic villages in Taiwan. Int J Microcirc Clin Exp. 1995; 15: 2127.
18. Styblo M, Delnomdedieu M, Thomas DJ. Biological mechanisms and toxicological consequences of the methylation of arsenic.In: Goyer RA, ed. Toxicology of Metals: Biochemical Aspects, Handbook of Experimental Pharmacology. Berlin, Germany: Springer-Verlag; 1995; 115: 401433.
19. Kitchen KT. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol. 2001; 171: 249261.
20. Buchet JP, Lauwerys R. Study of inorganic arsenic methylation by rat in vitro: relevance for the interpretation of observations in man. Arch Toxicol. 1985; 57: 125129.
21. Clark R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991; 324: 11491155.
22. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997; 277: 17751781.
23. Stamler MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA. 1992; 268: 877881.
24. Packer L. Metabolic and structural states of mitochondria, II: regulation by phosphate. J Biol Chem. 1961; 236: 214220.
25. Fowler BA, Woods JS, Schiller CM. Studies of hepatic mitochondrial structure and function: morphometric and biochemical evaluation of in vivo perturbation by arsenate. Lab Invest. 1979; 41: 313320.
26. Chen B, Burt PL, Goering BA, et al. In vivo 32-P nuclear magnetic resonance studies of arsenite induced changes in hepatic phosphate levels. Biochem Biophys Res Commun. 1986; 139: 228234.
27. Chin KV, Tanaka S, Darlington I, et al. Heat shock and arsenite increase expression of the multi-drug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem. 1990; 265: 221226.
28. Hansen ES. Shared risk factors for cancer and atherosclerosis: a review of the epidemiological evidence. Mutat Res. 1990; 239: 162179.
29. Germolec DR, Spalding J, Boorman DA, et al. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat Res. 1997; 386: 209218.
30. Salonen JT, Seppanen K, Lakka TA, et al. Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis. 2000; 148: 265273.
This article has been cited by other articles:
![]() |
J. C. States, S. Srivastava, Y. Chen, and A. Barchowsky Arsenic and Cardiovascular Disease Toxicol. Sci., February 1, 2009; 107(2): 312 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Hays, R. C. Lantz, L. S. Rodgers, J. J. Sollome, R. R. Vaillancourt, A. S. Andrew, J. W. Hamilton, and T. D. Camenisch Arsenic-Induced Decreases in the Vascular Matrix Toxicol Pathol, October 1, 2008; 36(6): 805 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bhatnagar Environmental Cardiology: Studying Mechanistic Links Between Pollution and Heart Disease Circ. Res., September 29, 2006; 99(7): 692 - 705. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. C. Bilszta, G. J. Dusting, and F. Jiang Arsenite Increases Vasoconstrictor Reactivity in Rat Blood Vessels: Role of Endothelial Nitric Oxide Function International Journal of Toxicology, July 1, 2006; 25(4): 303 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Navas-Acien, A. R. Sharrett, E. K. Silbergeld, B. S. Schwartz, K. E. Nachman, T. A. Burke, and E. Guallar Arsenic Exposure and Cardiovascular Disease: A Systematic Review of the Epidemiologic Evidence Am. J. Epidemiol., December 1, 2005; 162(11): 1037 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Chiou, S.-L. Wang, C.-J. Chen, C.-R. Deng, W. Lin, and T.-Y. Tai Arsenic ingestion and increased microvascular disease risk: observations from the south-western arseniasis-endemic area in Taiwan Int. J. Epidemiol., August 1, 2005; 34(4): 936 - 943. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-C. Lee, I-C. Ho, and T.-C. Lee Oxidative Stress Mediates Sodium Arsenite-Induced Expression of Heme Oxygenase-1, Monocyte Chemoattractant Protein-1, and Interleukin-6 in Vascular Smooth Muscle Cells Toxicol. Sci., May 1, 2005; 85(1): 541 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bhatnagar Cardiovascular pathophysiology of environmental pollutants Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H479 - H485. [Full Text] [PDF] |
||||
![]() |
N. V. Soucy, M. A. Ihnat, C. D. Kamat, L. Hess, M. J. Post, L. R. Klei, C. Clark, and A. Barchowsky Arsenic Stimulates Angiogenesis and Tumorigenesis In Vivo Toxicol. Sci., December 1, 2003; 76(2): 271 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Vineis Cancer as an evolutionary process at the cell level: an epidemiological perspective Carcinogenesis, January 1, 2003; 24(1): 1 - 6. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |